Abstracts Archive

Introduction: ENKTL is an aggressive disease and patients with early non upper aero digestive tract (NUAT) or advanced stage disease often exhibit an aggressive clinical course. Mitoxantrone hydrochloride liposome has demonstrated efficacy in relapsed/refractory ENKTL in a phase II clinical trial. M...

Introduction:Total skin electron therapy (TSET) is an effective treatment for cutaneous T-cell lymphomas (CTCL). However, the nuances of patient setup and treatment delivery present challenges for treatment verification. Objectives: To report on the utility of Cherenkov imaging, a novel mo...

Background: Mogamulizumab is approved to treat relapsed/refractory mycosis fungoides/Sézary syndrome (MF/SS). In the phase 3 MAVORIC study (N=372), mogamulizumab, given 1mg/kg weekly in cycle (C) 1 and then biweekly (Q2W), demonstrated superior efficacy vs vorinostat and a manageable safety profile...

PTX-100 is a potent small molecule that targets GGTase1, inhibiting a crucial post-translational modification required for the oncogenic activity of RAS family proteins. The clinical potential of PTX-100 was first highlighted in two Phase 1 dose-finding trials: one in solid tumors (TG-GTI-001) and o...

IntroductionPeripheral T-cell lymphomas (PTCL) are rare, heterogeneous, aggressive lymphomas. Current monotherapies have overall response rates (ORR) of <30% (except brentuximab vedotin for CD30+ ALCL). Duvelisib is an oral inhibitor of phosphatidylinositol 3-kinase-δ and -γ isoforms. PRIMO (NC...

DR-01 is a non-fucosylated human IgG antibody targeting CD94, a receptor selectively expressed on cytotoxic terminal effector CD8+T cells, γδT cells, and NK cells, leading to rapid depletion of target cells primarily by antibody-dependent cellular cytotoxicity, including fratricide (cyto...

Introduction:Mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL) are common subtypes of CTCLs. ALCANZA trial showed brentuximab vedotin (BV) significantly improved ORR4 (objective response rate lasting ≥ 4 months) in CD30+ CTCLs patients compared with conventional ...

Background: CTCL patients face unique challenges due to visible and progressive symptoms. The aim of this study was to understand how patients navigate the psychosocial impact of visible disease manifestations and maintain their sense of identity and social relationships.Methods: We...